Drug-Eluting Stents in the Management of Coronary Artery Disease: Implications for Payors and Hospitals

By James B. Hermiller  

Disease Management & Health Outcomes, Vol. 13, Iss. 1, 2005-01 ,pp. : 1-7

Adis International

Access to resources Recommend Favorite

Evaluation and Treatment of Depression (Part I): Benefits for Patients, Providers, and Payors

By Kramer Teresa L.  

Disease Management & Health Outcomes, Vol. 13, Iss. 5, 2005-01 ,pp. : 295-306

Adis International

Access to resources Recommend Favorite

Thiazolidinediones for Diabetes Mellitus: Considerations for Reimbursements by Third-Party Payors

By Andrew J. Palmer   William J. Valentine   Joshua A. Ray  

Disease Management & Health Outcomes, Vol. 12, Iss. 6, 2004-01 ,pp. : 363-375

Adis International

Access to resources Recommend Favorite

Adalimumab for Rheumatoid Arthritis: Considerations for Reimbursement by Third-Party Payors

By Leo van de Putte  

Disease Management & Health Outcomes, Vol. 12, Iss. 1, 2004-01 ,pp. : 1-8

Adis International

Access to resources Recommend Favorite

Law, Patient’s Rights and NHS Resource Allocation: Is Eurostar the Answer?

By McHale Jean  

Health Care Analysis, Vol. 14, Iss. 3, 2006-09 ,pp. : 169-183

Springer Publishing Company

Access to resources Recommend Favorite